Tulio Rodriguez is an Oncology physician. OpenAlex indexes 89 publications with 1,409 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2520 Elisha Avenue
Zion, IL 60099
Telephone
800-322-9183Provider last certified this registry record 28 Sept 2022.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202517 payments$33,504openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202510 payments
- GlaxoSmithKline, LLC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
44.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor44.7%Acyclovir100%Part D≥39 patientsAnti-infectives
18.3%Human Immunoglobulin G8.8%Xembify100%Part D<11 patientsFluoroquinolone Antibacterial5.1%Levofloxacin100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
11.7%Thalidomide Analog6.2%Lenalidomide100%Part D<11 patientsKinase inhibitor5.5%Calquence100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Leukemia & lymphoma/Leukemia and lymphoma
2025 - Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
Current Problems in Cancer Case Reports
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”